Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

ical centers throughout North America, Australia, Latin America, and Europe, and will again compare alemtuzumab-treated patients to Rebif-treated patients according to two co-primary endpoints: the time to sustained accumulation of disability, and the annualized relapse rate. Alemtuzumab will be dosed at 12 mg/day for five days by daily IV infusion, with a second dosing 12 months later of 12 mg/day for three days. All patients will be followed from their entry into the trial until two years from the date that the last patient is randomized to treatment. Alemtuzumab-treated patients will continue to have safety evaluations for at least three years after the last course of treatment. The companies anticipate filing for marketing approval of alemtuzumab for the treatment of MS in 2011.

Alemtuzumab is an investigational drug for the treatment of MS and must not be used outside of a formal clinical trial setting in MS patients. Physicians or patients seeking additional information about the CARE-MS I trial should contact Genzyme Medical Information at 1-800-745-4447, option 2 in the United States, + 31 35 6991499 in Europe, or visit http://www.clinicaltrials.gov.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) in which the immune system can attack the brain and spinal cord. The disease causes a wide range of symptoms including fatigue, difficulty walking, numbness, and vision problems, and can progress to cause severe disability. Relapsing-remitting MS is the most common form of this disease.

About Alemtuzumab

Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. The product was launched in its oncology indi
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Gary A. Puckrein , PhD, ... Forum (NMQF), today will present an award to ... Research and Manufacturers of America (PhRMA), for his ... behalf of PhRMA, and in conjunction with NMQF, Castellani ... awareness, start conversations, and increase diversity in clinical trials, ...
(Date:4/21/2015)... -- The North American dermatology diagnostic devices market is ... 2014 to 2019. Although mature markets (the U.S. and ... the dermatology diagnostic devices market, Mexico ... of 9.8% during the forecast period. The growth of ... such as rising incidences of skin disorders, increasing demand ...
(Date:4/21/2015)... April 21, 2015 Softheon, Inc., ... integration and business operation, has confirmed its status ... Centers of Medicare & Medicaid Services (CMS).  Under ... with access to the Federal Data Hub to ... into qualified health insurance plans. ...
Breaking Medicine Technology:National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 2National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 3North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 2North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 3Softheon Confirms Web Broker Entity (WBE) Status with the Centers of Medicare & Medicaid Services (CMS) 2
(Date:4/21/2015)... 2015 On April 8th, 2015, Choices ... at the world famous Avalon Hollywood. Organized by Debbie ... in TV and film, the EcoLuxe Lounge is a ... awards ceremonies and festivals throughout the year. A gathering ... and socially conscious products and services, this daylong event ...
(Date:4/21/2015)... Colmar, PA (PRWEB) April 21, 2015 ... Ichthyosis & Related Skin Types, Inc.® (FIRST) will publish ... ichthyosis. The campaign will run throughout the month of ... Voice. It Matters to Someone." The positioning was ... about this rare skin disorder and to help support ...
(Date:4/21/2015)... 21, 2015 Approximately 75 million Americans ... U.S. Environmental Protection Agency (EPA). On top of this, ... smoke increase the level of toxins found in the ... these harmful toxins is to increase consumption of broccoli. ... highest level of glucoraphanin – a long-lasting antioxidant – ...
(Date:4/21/2015)... 21, 2015 As a provider of ... found that their rehabilitation strategy, which involves various treatment ... relapses. In an effort to offer hope and encouragement ... their lives, Best Drug Rehabilitation has featured a series ... many successful graduates of their recovery program. , ...
(Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
Breaking Medicine News(10 mins):Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 3Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2
... Inc. and TPABenefits, Inc.,of San Antonio, TX announced ... INETICO system and the TPABenefits Web Portal. This ... Pre-Certification,and Wellness data source and allows Payors, TPA,s, ... Case Notes on the,TPABenefits Web Portal., The ...
... Calif., May 8 IRIDEX,Corporation (Nasdaq: IRIX ) ... financial results after the market closes on Tuesday, May ... host a conference,call with the investment community at 5:00 ... the results of the quarter and other business,developments., ...
... Viruses are masters of deception, duping their host,s cells ... has found that human cytomegalovirus (HCMV) can mimic a ... disrupting a cell,s primary anti-cancer mechanism. , Writing in ... University of Wisconsin-Madison and Harvard Medical School report that ...
... disease, osteoarthritis (OA) is the leading cause of disability in ... OA most often strikes the knee, particularly the inner aspect ... this vulnerable joint compartment is the knee adduction moment, an ... increase in the peak knee adduction moment is associated with ...
... More than 8,700 babies born each year in Washington to ... is,one of the best things a woman can do to ... time for Mother,s Day on May 11, the state,Department of ... Line,to provide pregnant women with more help when they,re ready ...
... MADISON, Wis., May 8 Let,s face it,Americans ... prove,positive, like when it promotes greater awareness and ... of cancer, lung cancer,causes almost twice as many ... today launched a national, multi-media public service,announcement (PSA) ...
Cached Medicine News:Health News:INETICO, Inc. Creates Data Interface with TPABenefits, Inc. Offering a Powerful Care and Claims Management Solution 2Health News:Virus mimics human protein to hijack cell division machinery 2Health News:Cane use may reduce risk of knee osteoarthritis progression 2Health News:Cane use may reduce risk of knee osteoarthritis progression 3Health News:Tobacco Quit Line Expands Services for Pregnant Women Who Smoke 2Health News:National Lung Cancer Partnership Launches Campaign to Raise Lung Cancer Awareness Among Women 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: